Get the Weekly Intelligence Brief — top committee picks every Sunday.

GMAB vs PEN

Genmab A/S vs Penumbra, Inc. — AI-powered side-by-side comparison
GMAB
Genmab A/S
60
Buy
VS
PEN
Penumbra, Inc.
67
Buy
MetricGMABPEN
AI Score 60 67
Price $30.82 $326.07
P/E Ratio 24.04× 79.78×
ROE 16.5% 12.4%
Revenue Growth YoY
Gross Margin 39.9% 67.8%
Debt / Equity 0.89× 0.14×
Dividend Yield 0.0% 0.0%
RSI (14) 72.5 79.6
Beta 0.685 0.701
Expected Upside +6.3%

AI Committee View

Current Innellis committee reasoning for GMAB versus PEN.
PEN leads by 7 points.

PEN scores 67/100 (Buy) versus GMAB at 60/100 (Buy).

GMAB Committee View
60% agreement
5 analysts

Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • EPS declining -25.3% YoY despite any revenue growth — Growth
  • RSI at 73 is in overbought territory — Technical
PEN Committee View
80% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • 2 consecutive earnings misses -- execution concerns — Growth
  • RSI at 80 is in overbought territory — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GMAB Full Analysis PEN Full Analysis